Evolus (EOLS) Total Non-Current Liabilities (2017 - 2022)
Evolus' (EOLS) quarterly Total Non-Current Liabilities came in at $159.5 million in Q4 2022, up 21.87% YoY from $130.9 million in Q4 2021, and down 2.46% on a QoQ basis from $163.5 million in Q3 2022.
Evolus (EOLS) Total Non-Current Liabilities (2017 - 2022) Analysis & Trends
Evolus (EOLS) has 6 years of Total Non-Current Liabilities data on file, last reported at $159.5 million in Q4 2022.
- Quarterly Total Non-Current Liabilities rose 21.87% year-over-year to $159.5 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $159.5 million (up 21.87% YoY) and the FY2022 annual result came in at $159.5 million, up 21.87% from the prior year.
- Total Non-Current Liabilities retreated to $159.5 million in Q4 2022, from $163.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $240.5 million in Q4 2020 to a low of $34.8 million in Q1 2018.
- A 5-year average of $116.2 million and a median of $117.3 million in 2020 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2018 — Total Non-Current Liabilities slumped 83.64% — and 2019, when it jumped 225.1%.
- Tracing EOLS's Total Non-Current Liabilities over 5 years: stood at $37.3 million in 2018, then surged by 212.14% to $116.3 million in 2019, then soared by 106.77% to $240.5 million in 2020, then sank by 45.58% to $130.9 million in 2021, then gained by 21.87% to $159.5 million in 2022.
- The last three Total Non-Current Liabilities figures came in at $159.5 million (Q4 2022), $163.5 million (Q3 2022), and $164.1 million (Q2 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 159.48 Mn |
| Sep 30, 2022 | 163.50 Mn |
| Jun 30, 2022 | 164.06 Mn |
| Mar 31, 2022 | 153.41 Mn |
| Dec 31, 2021 | 130.87 Mn |
| Sep 30, 2021 | 112.82 Mn |
| Jun 30, 2021 | 128.73 Mn |
| Mar 31, 2021 | 128.91 Mn |
| Dec 31, 2020 | 240.48 Mn |
| Mar 31, 2020 | 117.33 Mn |
| Dec 31, 2019 | 116.30 Mn |
| Jun 30, 2019 | 114.43 Mn |
| Mar 31, 2019 | 99.67 Mn |
| Dec 31, 2018 | 37.26 Mn |
| Sep 30, 2018 | 37.31 Mn |
| Jun 30, 2018 | 35.20 Mn |
| Mar 31, 2018 | 34.81 Mn |
| Dec 31, 2017 | 227.78 Mn |